![Martin Vogelbaum](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Vogelbaum
Fondatore presso
Ajax Therapeutics, Inc.
Profilo
Martin A. Vogelbaum is the founder of Gloucester Pharmaceuticals, Inc., Ajax Therapeutics, Inc. Current positions include Director & Managing Partner at Inning One Ventures, Partner at Rho Capital Partners, Inc. since 2005, and Non-Managing Member at RMV VI LLC.
Former roles include Director at Nuvelo, Inc. from 1997 to 2005, Director at Middlebrook Pharmaceuticals, Inc. from 2007 to 2010, Independent Director at Inotek Pharmaceuticals Corp.
from 2014 to 2016, Director at Mersana Therapeutics, Inc., AqueSys, Inc., SARcode Bioscience, Inc., Nora Therapeutics, Inc., and Medpace Research, Inc. from 2013 to 2014.
Served as Lead Independent Director at CARA Therapeutics, Inc. from 2015 to 2022, Vice President-Business Development at Celgene Corp.
from 2015 to 2017, General Partner at Oxford Bioscience Partners and Apple Tree Venture Management LLC, Associate at Memorial Sloan Kettering Cancer Center, and Advisor at The New York City Investment Fund Manager, Inc. Education includes undergraduate studies at The Trustees of Columbia University in The City of New York.
Posizioni attive di Martin Vogelbaum
| Società | Posizione | Inizio |
|---|---|---|
Rho Capital Partners, Inc.
 Rho Capital Partners, Inc. Investment ManagersFinance Rho Capital Partners invests in companies located in the United States. The firm focuses on companies operating across a broad range of sectors. It participates in seed, early and later stage transactions. | Investitore di Private Equity | 01/01/2005 |
RMV VI LLC | Corporate Officer/Principal | - |
Ajax Therapeutics, Inc.
 Ajax Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in R&D, clinical trial and manufactures hematologic cancer therapeutics | Fondatore | - |
Precedenti posizioni note di Martin Vogelbaum
| Società | Posizione | Fine |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01/01/2017 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye | Direttore/Membro del Consiglio | 01/01/2016 |
| NEPHROGENEX INC | Direttore/Membro del Consiglio | 01/05/2014 |
Gloucester Pharmaceuticals, Inc.
 Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops products for the treatment of cancer patients | Fondatore | 26/04/2011 |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pulsatile drug products | Direttore/Membro del Consiglio | 22/03/2010 |
Formazione di Martin Vogelbaum
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
73
Relazioni di 1° grado
19
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 19 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Nuvelo, Inc.
 Nuvelo, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs using genomic technologies | Health Technology |
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pulsatile drug products | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye | Health Technology |
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops products for the treatment of cancer patients | Health Technology |
Mersana Therapeutics, Inc.
 Mersana Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures antibody drug conjugates to improve patient outcomes in multiple oncology indications | Health Technology |
CARA Therapeutics, Inc.
 CARA Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed | Health Technology |
AqueSys, Inc.
 AqueSys, Inc. Medical SpecialtiesHealth Technology Develops surgical products for surgeons | Health Technology |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rho Capital Partners, Inc.
Rho Capital Partners, Inc. Investment ManagersFinance Rho Capital Partners invests in companies located in the United States. The firm focuses on companies operating across a broad range of sectors. It participates in seed, early and later stage transactions. | Finance |
Medpace Research, Inc.
 Medpace Research, Inc. Medical DistributorsDistribution Services Develops drugs and novel therapies for kidney diseases | Distribution Services |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates cancer hospital | Health Services |
The New York City Investment Fund Manager, Inc.
 The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager invests in the companies located in the United States. The firm focuses on fintech, health IT, life sciences and advanced manufacturing sectors. It participates in early and growth stage capital transactions. The firm acquires minority interest. | Finance |
Apple Tree Venture Management Llc//vc
 Apple Tree Venture Management Llc//vc Investment ManagersFinance Apple Tree Partners invests in companies located in the United States. The firm focuses on the life sciences sector. It provides financing for seed, early and later stage capital requirements. | Finance |
Nora Therapeutics, Inc.
 Nora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments for infertility and miscarriages | Health Technology |
RMV VI LLC | |
Ajax Therapeutics, Inc.
Ajax Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in R&D, clinical trial and manufactures hematologic cancer therapeutics | Commercial Services |
